Under Armour Inc Class A vs Vir Biotechnology Inc. Common Stock — how do they compare? Under Armour Inc Class A trades at $4.63 (market cap $2.08B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Under Armour Inc Class A for 19 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| UA | VIR | |
|---|---|---|
Market Cap | $2.08B | $1.80B |
Volume | 2,142,599 | 1,782,836 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.88 | $11.78 |
52-Week Low | $3.96 | $5.12 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $3.06B | $1.36B |
Signals from Pluang's Aura AI — not financial advice
Under Armour (UA) trades at $4.76, down 0.63% with a bullish technical signal despite negative profitability metrics. The company reported mixed quarterly earnings with two beats and one miss, while revenue declined to $4.9B in 2026 with a net loss of $492M. Analyst sentiment is divided with 40% buy ratings, though recent news highlights revenue guidance cuts and competitive pressures.
The outlook remains challenging with persistent revenue declines and negative margins offset by attractive valuation multiples. Investment opportunity lies in potential turnaround execution, while risks include sustained consumer demand weakness and execution missteps in a highly competitive athletic apparel market.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →